)
Genetic Signatures (GSS) investor relations material
Genetic Signatures Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 FY2026 sales reached $3 million, reflecting seasonal respiratory testing rates in Australia.
Organisational restructuring implemented, resulting in 30 redundancies and estimated annual cost savings of $5 million from FY2027.
Signed a ten-year supply agreement with Hvidovre Hospital in Denmark for equipment and reagents, targeting 28,000 clinical samples in year one with 3% annual growth.
Transitioned elements of product development to contract research organisations to enhance flexibility and reduce fixed costs.
Financial highlights
Cash and term deposits totaled $25.7 million as of 31 March 2026.
Receipts from customers for the quarter were $3.7 million.
Net operating cash outflow for the quarter was $3.5 million.
Net investing cash outflow was $0.3 million, mainly for equipment investments.
Payments to Directors, including the CEO, totaled $0.3 million for the quarter.
Outlook and guidance
Operating in a highly competitive environment with uncertainty around the Australian flu season, which may impact Q4 FY2026 revenues.
Focused on advancing the EasyScreen molecular diagnostic platform in established and new markets.
Organisational restructure and strong balance sheet position the company to pursue commercial partnerships and new market opportunities.
- Revenue down 42%, net loss up 27%, but FDA clearance opens US growth path.GSS
H2 202427 Mar 2026 - Revenue up to $8.7m, margin down, with U.S./EMEA growth and cost discipline in focus.GSS
H1 202625 Feb 2026 - Sales up 136% to $8.5M, gross margin 59%, loss $15.2M, US launch delayed, $40.8M cash.GSS
H1 202524 Dec 2025 - Revenue up 63% to $15.9m, gross margin 55%, first US contracts, and $30.9m cash reserves.GSS
H2 202523 Nov 2025 - FY25 revenue up 66% to $14.4m, with record Q1 FY26 sales and all AGM resolutions approved.GSS
AGM 2025 Presentation16 Nov 2025 - Sales up 20% sequentially, strong US contracts, and $28.2M cash support global expansion.GSS
Q1 2026 TU20 Oct 2025 - Quarterly sales rose 52% sequentially, with strong cash reserves and new US contracts signed.GSS
Q4 2025 TU21 Jul 2025 - Strategic alliance launches integrated, automated infectious disease testing for global labs.GSS
Partnership21 Jul 2025 - Sales up 294% year-over-year, with $41.3M cash and strong US market momentum.GSS
Q1 2025 TU13 Jun 2025
Next Genetic Signatures earnings date
Next Genetic Signatures earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)